Steris acquires Synergy Health, a UK-based outsourcing company focused on sterilization, for &1.9 billion USD.
Steris offered to acquire Synergy Health for $1.9 billion in cash and stocks. Steris, a company specializing in infection prevention, contamination control, surgical, and critical care technology, will benefit from the UK-based Synergy Health, specializing in outsourced sterilization services. In fiscal 2014, Synergy generated approximately $604 million in revenue and approximately $161 million in adjusted earnings before EBITDA.
Upon closing, expected in March 2015 according to a press release, the combined business will have approximately $2.6 billion in annual revenue. The acquisition will save the new company approximately $30 million annually in pre-tax cost savings due to a lowered tax rate. Similar to many mergers and acquisitions in the past year that have been dependent upon tax inversion, Steris will see a lowered tax rate of 25%, as opposed to the US corporate income tax rate of 35%, when combined with the UK company.
Source: Steris
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.